14 results about "Drug specific IgE" patented technology

The invention discloses a polypeptide oligonucleotide conjugate and application thereof. The polypeptide oligonucleotide conjugate comprises (1) a polypeptide combined with an LRP2 receptor and (2) one or two oligonucleotide drugs used for regulating and controlling kidney target gene expression. The conjugate uses an LRP2 targeting peptide to specifically deliver a siRNA drug to the kidney.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

The present application relates to the technical field of bioinformatics and drug evaluation, and particularly relates to a method for constructing an organoid drug sensitivity evaluation model based on multi-omics fusion, comprising synchronously collecting morphokinetic time sequence images and multi-time point single-cell multi-omics data of organoids, obtaining paired morphological and molecular dynamic data, extracting cell state factors through coupled non-negative tensor decomposition, constructing a non-equilibrium free energy landscape under drug disturbance, quantifying the loss degree of molecular system robustness from two dimensions of geometric deformation and topological structure, detecting cross-scale causal relationships and constructing a drug disturbance entropy index. In the present application, the drug effect is evaluated from the physical nature of the loss of biological system robustness, replacing the traditional correlation analysis method, realizing the unification of quantitative evaluation of drug sensitivity and explanation of the mechanism of action, effectively distinguishing drug specific action and non-specific stress, and being suitable for personalized tumor treatment and new drug research and development.

The invention discloses an alkynylation dihydroartemisinic acid probe, a biotin-dihydroartemisinic acid probe and a preparation method and application of the alkynylation dihydroartemisinic acid probe. The structural formula of the alkynylated dihydroarteannuic acid is as shown in formula 1. And a'biotin-dihydroartemisinic acid 'probe structure is constructed. And co-incubating the probe and a cell lysis solution, co-incubating a lysis solution-probe mixed solution and streptavidin magnetic beads, and eluting to obtain the drug-specific binding protein. According to the invention, the action target of dihydroartemisinin in disease treatment can be quickly, simply and conveniently found.

The invention discloses a training method for decoupling into a drug response migration prediction model, and the method comprises the following steps: a drug specificity training step, extracting, using a drug-specific encoder, a feature shared between the first unlabeled cell line sample data constituting the source domain and the first unlabeled clinical sample data constituting the target domain and associated with the particular drug response; a decoupling forming step: a decoupling forming step; a second encoder capable of extracting a trained source domain of features independent of the particular drug response in second unlabeled cell line sample data and a third encoder capable of extracting a trained target domain of features independent of the particular drug response in second unlabeled clinical sample data by the drug-specific encoder the encoder is used for splicing the output of the drug specificity encoder and the output of the third encoder of the trained target domain, so as to obtain synthetic sample data; the synthetic data is then used to train the drug-specific encoder, thereby obtaining the trained drug-specific encoder, the method and apparatus decouple the cell line and clinical inputs into features related and independent of drug response and innovatively utilize the synthetic data to augment the dataset, and the method and apparatus can be used to identify the drug-specific encoder. And the drug sensitivity of clinical cancer patients is accurately predicted.

This invention provides a bispecific antibody targeting tissue factors, an antibody-drug conjugate (ADC), its preparation method, and its application, belonging to the field of biopharmaceutical preparation technology. The bispecific antibody provided by this invention can efficiently target tissue factors in tumor cells, exhibiting advantages such as strong affinity and high endocytosis efficiency. This invention also provides an ADC, which, under the action of the bispecific antibody, specifically binds to tumor surface antigens and is internalized into tumor cells, achieving precise drug delivery for antitumor drugs. The ADC provided by this invention exhibits good tumor-suppressing effects in both cell and animal models, and is non-toxic and harmless to animals, demonstrating excellent potential for cancer treatment.

The present invention relates to the technical field of medicine, and relates in particular to a molecule having a targeting function. The molecule having a targeting function can specifically deliver a drug to a specific cell, which facilitates precise programming of a specific cell in the body, a therapeutic effect of the drug is produced, and consequently drug dosage and side effects are greatly reduced, and the effect of precise treatment to cells in the body is achieved.

This invention relates to the field of pharmaceutical chemistry, specifically to a Devimistat derivative with mitochondrial targeting function, its preparation method, and its application in antitumor drugs. This derivative covalently couples the mitochondrial-attractant 3-aminopropyl(triphenyl)phosphine bromide (TPP) group to the antitumor active molecule Devimistat, utilizing the affinity of the TPP cation for the mitochondrial transmembrane potential to drive the drug's specific accumulation in the mitochondrial matrix. While retaining the original drug's interference with the tricarboxylic acid cycle and inhibition of PDH and KGDH complex activity, this derivative significantly increases the effective drug concentration within tumor cells, thus solving the problem of limited efficacy of Devimistat due to its lack of targeting.

The invention relates to a medicine for improving expression of lysosome related transmembrane protein 4B and a screening method of the medicine, and belongs to the technical field of medicine screening. According to the invention, a fluorescent marker is accurately inserted into a target protein LAPTM4B gene locus, so that real-time monitoring of dynamic change of endogenous protein is realized; meanwhile, membrane protein CD63 is introduced as an internal reference signal, a high-throughput automatic drug screening and image analysis system is utilized to quantitatively screen compounds in a large-scale drug library, finally, drugs capable of improving LAPTM4B expression are screened out, and a new direction is provided for subsequent research on therapeutic targets related to lysosome-related transmembrane protein 4B. Meanwhile, the screened medicine is good in specificity, LAPTM4B expression can be improved, but CD63 is not affected, so that time-space precise control over LAPTM4B activity can be achieved, and the method has important significance in construction of an in-vitro / in-vivo instantaneous activation model.

Provided are modifications of human interleukin-2 (IL-2) and interferon α (IFNα), a fusion protein formed by modified IL-2, IFNα or both of IL-2 / IFNα and an Fc, and design, preparation and use of the fusion protein. By changing the binding capacity of IFNα to a receptor thereof by means of gene mutation, a superior fusion protein is acquired, which may overcome the defects of weak specificity and serious adverse effects of existing drugs.

The present invention relates to a drug delivery system with a micelle structure comprising a PEG2000-DSPE polymerized lipid and an APTEDB-PEG2000-DSPE polymer, and a preparation method thereof. The drug delivery system targets extra-domain B of fibronectin (EDB-FN), which is overexpressed in a brain tumor, and can pass through the blood-brain barrier (BBB) or the blood-brain tumor barrier (BBTB) to deliver a drug specifically to the brain tumor cells. In addition, the present invention can provide a pharmaceutical composition for diagnosing or treating a brain tumor, comprising the drug-loaded drug delivery system as an active ingredient. The composition can be accumulated inside the brain tumor and incorporated into the tumor cells to specifically inhibit tumor growth, and thus can be efficiently utilized for diagnosing or treating a brain tumor.

The application discloses tumor-related fibroblasts which can be targeted to die, the tumor-related fibroblasts carry polynucleotide fragments of sequences such as SEQ ID No:1 in chromosomes, and the tumor-related fibroblasts have morphology and in-vitro growth rate comparable to other tumor-related fibroblasts.The tumor-related fibroblasts can be specifically induced to die by drugs when co-cultured with other tumor-related fibroblasts, and the drugs are ganciclovir, and the ganciclovir drug concentration ranges from 1 to 100 μM.The application provides a novel and convenient cell construction method for studying the functions of different subtypes of CAFs and application thereof, and the novel CAFs can be targeted to die under the treatment of ganciclovir, weaken the effect of the CAFs of the type on co-cultured tumor cells, and help effectively distinguish the roles of different subtypes of CAFs in tumor occurrence and development.

Methods are described that include an integrated, multi-scale, artificial intelligence-based system that reconstructs drug-specific pharmacogenomic networks and their constituent functional subnetworks. The system uses features of the functional topology of the three-dimensional architecture of drug-modulated spatial contacts in chromatin space. Discovery of drug pharmacogenomic networks is performed by selecting candidate SNPs with the aid of imputation, determining predictive causal relationships of the SNPs using machine learning and deep learning, probing spatial genomes as determined by chromosome conformation capture analysis using causal relationship SNPs, combining targeted genes controlled by the same cell and tissue-specific enhancers, and using different data sources and metrics to reconstruct pharmacogenomic networks based on results of genome-wide association studies. The pharmacogenomic networks are deconstructed into their constituent functional and adverse event subnetworks using a knowledge-based segmentation approach for application in clinical decision support, drug repurposing, and in silico drug discovery.

A polypeptide-oligonucleotide conjugate and use thereof. The polypeptide-oligonucleotide conjugate comprises (1) a polypeptide that binds to an LRP2 receptor, and (2) one or two oligonucleotide drugs for regulating the expression of a kidney target gene. The conjugate specifically delivers an siRNA drug to the kidney using the LRP2-targeting peptide.